Breakthrough! Eli Lilly’s Weight Loss Drug Triumphs in Reducing Diabetes Risk – Discover the Hope for a Healthier Future
Eli Lilly’s groundbreaking weight loss drug, tirzepatide, has demonstrated remarkable efficacy in reducing the risk of Type 2 diabetes by 94% in obese or overweight adults with prediabetes, according to preliminary results from a long-term study published Tuesday. The study, which spanned nearly three years, revealed that participants on the highest weekly dose of tirzepatide experienced an average weight loss of 22.9%, compared to just 2.1% for those on a placebo.
Tirzepatide, the active ingredient in Eli Lilly’s Zepbound and Mounjaro, could significantly delay the onset of diabetes in individuals with prediabetes—those with elevated blood sugar levels not yet severe enough to be classified as Type 2 diabetes. With more than a third of Americans experiencing prediabetes—a condition often reversible through diet and exercise—these findings underscore the drug’s potential long-term health benefits.
The phase three trial, involving over 1,000 adults and lasting 176 weeks with a follow-up period of 17 weeks post-treatment, is the most extensive study on tirzepatide to date. While those who discontinued the drug saw a resurgence in weight and progression towards diabetes, they still had an 88% lower risk of developing the disease compared to placebo recipients.
Tirzepatide works by mimicking gut hormones GLP-1 and GIP, which help suppress appetite and regulate blood sugar. The drug’s safety profile remained consistent with earlier studies, with mild to moderate gastrointestinal side effects being the most common.
Eli Lilly plans to present these findings at a medical conference in November and will submit them to a peer-reviewed journal. Dr. Jeff Emmick, Eli Lilly’s senior VP of product development, emphasized that these results reinforce the clinical benefits of long-term therapy for individuals with obesity and prediabetes.
As the popularity of GLP-1-based medications like Zepbound and Mounjaro continues to rise, this study highlights their wide-ranging potential beyond weight loss, inspiring further clinical research.
Original Story https://www.cnbc.com/2024/08/20/eli-lilly-weight-loss-drug-cuts-risk-of-developing-diabetes-in-trial.html
Category :
Tags:
